Clinical trials: PET-CT
Oral Carcinoma
68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma
FAPI is a fibroblast activation protein inhibitor and 68Ga-FAPI-04 is a potential new imaging agent for imaging of carcinoma. 68Ga-FAPI-04 PET/CT is helpful to clarify the benign, malignant and invasive range of the oral…
- Trial name
- NCT05003427
- Testing
- 68Ga-FAPI-04
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer.
- Trial name
- NCT01916122
- Testing
- Fluorestradiol (FES), PET/CT Imaging
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Functional Medical Imaging Quantization in Prostate Cancer
Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist.
- Trial name
- QUIP (NCT03376360)
- Where
- France
- Volunteers
- 61 people
- Sponsor
- University Hospital, Brest
Malignant Neoplasm
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.
- Trial name
- NCT06688188
- Testing
- 68Ga-JH12
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Glioblastoma Multiforme
18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme
This is a pilot study to determine uptake of PET tracer 18F-PSMA-1007 in primary glioblastoma.
- Trial name
- PSMA-GBM (NCT04588454)
- Testing
- 18F-PSMA-1007 PET tracer
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Radboud University Medical Center
Lymphoma
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
To develop a novel method for evaluating treatment response in lymphoma by utilizing PET/CT imaging data from patients with high-metabolic lymphoma.
- Trial name
- NCT06795113
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Ruijin Hospital
Pleural Effusion, Malignant
The Value of PET-CT in Pleural Effusions
The investigators aim is to asses the diagnostic power of 18F-FDG PET-CT in discriminating malignant from nonmalignant causes in patients with a recurrent unilateral pleural effusion of unknown origin.
- Trial name
- NCT03272997
- Where
- Denmark
- Volunteers
- 112 people
- Sponsor
- Naestved Hospital
Healthy, Tomography
Effect of Respiratory Motion on Positron Emission Tomography Imaging
This study will determine how breathing motions may affect positron emission tomography (PET) scans. It has been discovered that the quality of PET scans varies according to which part of the breathing cycle patients hold their…
- Conditions
- Healthy, Tomography, Emission Computed
- Trial name
- NCT00088361
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Cancer, Metastasis
PET-CT and Circulating Tumor Cells in Colorectal Cancer
The purpose of this study is to identify an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria.
- Trial name
- NCT01163305
- Testing
- Chemotherapy
- Where
- Hong Kong
- Volunteers
- 84 people
- Sponsor
- Chinese University of Hong Kong
HCC
18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib
The principal objective of this study is to explore the role of 18F-FDG PET in identifying sorafenib-induced metabolic shift in HCC, thus in predicting treatment response and disease outcome in advanced HCC patients candidate to…
- Trial name
- NCT02977754
- Testing
- This is an observational study
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Istituto Clinico Humanitas
Malignancy
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
This is an open-label whole-body PET/CT study for investigating the value of Al18F-NOTA-FAPI PET/CT in patients with malignant tumors expressing fibroblast-activated proteins
- Trial name
- NCT05749302
- Testing
- Al18F-NOTA-FAPI
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colo-rectal Cancer, Recurrence
F-18 FDG- PETCT in Staging and Recurrent Colorectal Cancer
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.
- Trial name
- NCT03572595
- Testing
- F-18 FDG-PET/CT
- Volunteers
- 45 people
- Sponsor
- Assiut University
Acute Ischemic Stroke
PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke
Adult patients who are diagnosed with an acute supratentorial ischemic stroke within 48 hrs of onset will be enrolled into the study. Participants will undergo both a CT Scan and PET scan within 7 days of onset.
- Trial name
- NCT04571177
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Alberta
Head and Neck Cancer
Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer
Head and neck cancer (HNC) is the 6th most common cancer worldwide. In the last decade, there has been made substantial improvements in diagnosis, staging and treatment of HNC.
- Trial name
- NCT02965001
- Testing
- 68Ga-NOTA-AE105
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Neuroendocrine Tumors
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors.
- Trial name
- NCT07102056
- Testing
- 18F-AlF-NOTA-Octreotide PET-CT or PET-MR
- Volunteers
- 152 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Multiple Myeloma, Bone Metastases
Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner
To assess the added value of magnetic resonance imaging (MRI) of the skeleton compared to other validated techniques for the detection of bone lesions in patients with multiple myeloma.
- Trial name
- MM-ZTE (NCT05381077)
- Testing
- MRI
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Alzheimer Disease (AD)
[18F]F-AraG PET Imaging in Alzheimer's Disease
This study evaluates the use of [18F]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD).
- Trial name
- NCT07611357
- Testing
- Drug: [18F]F-AraG (PET tracer)
- Volunteers
- 10 people
- Sponsor
- CellSight Technologies, Inc.
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis - Extension Study
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid…
- Trial name
- VIP-E (NCT01866592)
- Testing
- Adalimumab
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania
Prostate Cancer (Diagnosis)
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
- Trial name
- NCT07615101
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 365 people
- Sponsor
- Norroy Bioscience Co., LTD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.